Long-term sotatercept treatment of pulmonary arterial hypertension: pooled analysis of efficacy and safety

Extract Sotatercept is a first-in-class activin-signalling inhibitor approved for treatment of pulmonary arterial hypertension (PAH) [1–3]. SOTERIA ( NCT07218029 ) is a phase III, single-arm, open-label, follow-up study assessing long-term safety, tolerability and efficacy of sotatercept in adults with PAH who participated in a parent sotatercept study [4]. Analysis of pooled data from time of SOTERIA entry through 1 year (mean 15 months) of treatment with sotatercept was previously reported [4]. Here, we provide a novel, more comprehensive and updated analysis of SOTERIA participants from the time of sotatercept initiation (during the parent study or, for those receiving placebo throughout the parent study, at rollover into SOTERIA) up to a median of 2.5 years.